J&J'S vaccine pause should be lifted -CDC advisers

Video Credit: Reuters - Politics
Published on April 24, 2021 - Duration: 01:50s

J&J'S vaccine pause should be lifted -CDC advisers

Use of Johnson & Johnson's COVID-19 vaccine should be resumed in the United States, advisers to U.S. health regulators said on Friday, after weighing evidence of the shot's link to extremely rare but potentially deadly blood clots.

Lisa Bernhard produced this report.


J&J'S vaccine pause should be lifted -CDC advisers

The use of Johnson & Johnson's COVID-19 vaccine should be resumed in the U.S. despite evidence that it is linked to extremely rare but potentially deadly blood clots, advisers to the U.S. Centers for Disease Control and Prevention recommended on Friday.

UNIDENTIFIED SPEAKER FROM ADVISORY PANEL SESSION: "So the vote is 10 in favor, four opposed and one abstention.

The motion carries.

The Janssen COVID vaccine is recommended for persons 18 years of age and older in the U.S. population under the FDA's Emergency Use Authorization." The recommendation paves the way for J&J's shot to begin going into arms again in the U.S. once they are confirmed by regulators.

CDC director Dr. Rochelle Walensky, speaking earlier in the day, was among the top health officials hoping for a quick return to the vaccine's use.

“I think the FDA and I both feel strongly and the CDC feel strongly that we need to act swiftly after that analysis but I do think that there's plenty of people who are interested in the J&J vaccine if just for convenience as well as for single dose option.” The FDA will update the emergency use authorization for the vaccine to include information about the risk and how to recognize and treat the condition, J&J executives told the panel.

Dr. Beth Bell, a member of the advisory panel and a clinical professor at the University of Washington in Seattle, said (quote), "The benefits do clearly outweigh the risk from a population and individual perspective,” adding (quote), “It's admittedly an extremely small risk and smaller than many other risks that we choose to take every day." Late on Friday, the New York Times reported the FDA officially ended its recommended pause on the J&J vaccine.

You are here


💡 newsR Knowledge: Other News Mentions


Food and Drug Administration

Agency of the US Department of Health and Human Services
Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Credit: IndiaTimes - Published 1 week ago

Ocugen Inc said on Thursday it would no longer pursue an emergency use authorization for its Covid-19 vaccine candidate, Covaxin, and would instead aim to file..
Credit: IndiaTimes - Published 1 week ago






Emergency Use Authorization

Granted by the Food and Drug Administration in the US
Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Credit: IndiaTimes - Published 1 week ago

Related videos from verified sources

CDC Advisers Recommend Pfizer COVID-19 Vaccine for Kids Ages 12 to 15 01:06
Video credit: Cover Video STUDIO - Published on May 14, 2021 

CDC moves to approve vaccines for kids 00:39
Video credit: 23ABC News | Bakersfield - Published on May 13, 2021 

'Will open doors for them': Gupta says vaccines mean more freedoms for kids 03:41
Video credit: Bleacher Report AOL - Published on May 12, 2021 

You might like